Vertex Pharmaceuticals is a biotechnology business based in the US. Vertex Pharmaceuticals shares (VRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $463.13 – an increase of 7.16% over the previous week. Vertex Pharmaceuticals employs 6,100 staff and has a trailing 12-month revenue of around $11.7 billion.
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Vertex Pharmaceuticals stock price (NASDAQ: VRTX)
Use our graph to track the performance of VRTX stocks over time.
Is it a good time to buy Vertex Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Vertex Pharmaceuticals price performance over time
Historical closes compared with the close of $433.61 from 2025-11-28
1 week (2025-11-26)
0.33%
1 month (2025-11-04)
2.83%
3 months (2025-09-04)
9.24%
6 months (2025-06-04)
-2.75%
1 year (2024-12-04)
-6.55%
2 years (2023-12-04)
23.67%
3 years (2022-12-02)
34.93%
5 years (2020-12-04)
89.91%
Is Vertex Pharmaceuticals stock undervalued or overvalued?
Valuing Vertex Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vertex Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Vertex Pharmaceuticals's P/E ratio
Vertex Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 30x. In other words, Vertex Pharmaceuticals shares trade at around 30x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Vertex Pharmaceuticals's PEG ratio
Vertex Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5801. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Vertex Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Vertex Pharmaceuticals's EBITDA
Vertex Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.7 billion.
The EBITDA is a measure of a Vertex Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Vertex Pharmaceuticals financials
Revenue TTM
$11.7 billion
Operating margin TTM
40.27%
Gross profit TTM
$6.2 billion
Return on assets TTM
12.04%
Return on equity TTM
22.31%
Profit margin
31.35%
Book value
$68.20
Market Capitalization
$111.2 billion
TTM: trailing 12 months
Vertex Pharmaceuticals's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Vertex Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Vertex Pharmaceuticals's total ESG risk score
Total ESG risk: 30.84
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Vertex Pharmaceuticals's overall score of 30.84 (as at 12/31/2018) is nothing to write home about – landing it in it in the 44th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Vertex Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Vertex Pharmaceuticals's environmental score
Environmental score: 5.65/100
Vertex Pharmaceuticals's environmental score of 5.65 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Vertex Pharmaceuticals's social score
Social score: 24.22/100
Vertex Pharmaceuticals's social score of 24.22 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Vertex Pharmaceuticals's governance score
Governance score: 12.46/100
Vertex Pharmaceuticals's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Vertex Pharmaceuticals's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Vertex Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Vertex Pharmaceuticals has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Vertex Pharmaceuticals Inc was last rated for ESG on: 2019-01-01.
Total ESG score
30.84
Total ESG percentile
44
Environmental score
5.65
Environmental score percentile
8
Social score
24.22
Social score percentile
8
Governance score
12.46
Governance score percentile
8
Level of controversy
2
Vertex Pharmaceuticals share dividends
We're not expecting Vertex Pharmaceuticals to pay a dividend over the next 12 months.
Have Vertex Pharmaceuticals's shares ever split?
Vertex Pharmaceuticals's shares were
split on a 2:1 basis on 23 August 2000
. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Vertex Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Vertex Pharmaceuticals shares which in turn could have impacted Vertex Pharmaceuticals's share price.
Vertex Pharmaceuticals share price volatility
Over the last 12 months, Vertex Pharmaceuticals's shares have ranged in value from as little as $362.5 up to $519.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vertex Pharmaceuticals's is 0.322. This would suggest that Vertex Pharmaceuticals's shares are less volatile than average (for this exchange).
Vertex Pharmaceuticals overview
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG. ; Moderna, Inc. ; and Entrada Therapeutics, Inc.
Frequently asked questions
null What percentage of Vertex Pharmaceuticals is owned by insiders or institutions? Currently 0.141% of Vertex Pharmaceuticals shares are held by insiders and 97.287% by institutions.How many people work for Vertex Pharmaceuticals? Latest data suggests 6,100 work at Vertex Pharmaceuticals.When does the fiscal year end for Vertex Pharmaceuticals? Vertex Pharmaceuticals's fiscal year ends in December.Where is Vertex Pharmaceuticals based? Vertex Pharmaceuticals's address is: 50 Northern Avenue, Boston, MA, United States, 02210What is Vertex Pharmaceuticals's ISIN number? Vertex Pharmaceuticals's international securities identification number is: US92532F1003What is Vertex Pharmaceuticals's CUSIP number? Vertex Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 92532F100
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
